- $4.98m
- $12.43m
- $1.73m
Brief: Volitionrx - Advances Nu.Q Nets Platform Towards Commercialization
Brief: VolitionRX Limited Announces First Quarter 2026 Financial Results
Brief: Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna
Brief: Volition Announces First Ever Automated Nu.Q® Vet Cancer Test With Fujifilm Vet Systems
Brief: Volitionrx Announces Breakthrough Clinical Data For Nu.Q® Vet Cancer Test In Cats
Brief: Volitionrx Ltd Enters Amended Securities Purchase Agreement
Brief: Volitionrx Limited Announces Pricing Of $6.0 Million Underwritten Public Offering Of Common Stock And Common Stock Warrants
Brief: Volitionrx Limited Announces Proposed Underwritten Public Offering Of Common Stock
Marketing And Services Agreement With Hologic
Brief: Volition Signs First Human Out Licensing Deal
Brief: Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1 Concentrations Are Closely Associated With Sepsis And Organ Failure
Brief: VolitionRx Updates Progress Of Nu.Q NETs Test Adoption
Brief: VolitionRx Ltd May Offer & Sell Shares Of Common Stock Having Offering Price Of Up To $7.5 Mln - SEC Filing
Brief: Volitionrx Limited Announces Full Fiscal Year 2024 Financial Results And Business Update
Brief: Volition Announces Two Poster Presentations At Esmo's European Lung Cancer Congress 2025
Brief: VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
Brief: Volition Signs First Ever Nu.Q Vet Cancer Test Automation Agreement With Fujifilm Vet Systems
Brief: VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering
Brief: Volitionrx Ltd Files For Mixed Shelf Of Up To $100 Million - SEC Filing